REG - Intuitive Invests.Gp - Investment in CardiNor AS

Intuitive InvestmentsAnnouncement

31/03/2021 12:05

RNS Number : 1435U
  
Intuitive Investments Group plc
  
31 March 2021
  
 

31 March 2021
Intuitive Investments Group plc
Investment in CardiNor AS
Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £125,000 to acquire ordinary shares in CardiNor AS ("CardiNor"), representing a 1.8 per cent. interest in CardiNor's enlarged share capital.  
CardiNor is a Norwegian biotech company established in June 2015 to commercialise the development of secretoneurin ("SN"), an important new biomarker for cardiovascular disease ("CVD"). SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in all major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. CardiNor has completed development of a research assay based on immunoassay technology to measure SN in blood and the assay is under further clinical development, including to obtain a CE mark. More information can be found at: https://cardinor.com/. 
In the year ended 31 December 2020, per CardiNor's unaudited management accounts, it achieved a loss after tax of approximately £141,000 and, as at 31 December 2020, had net assets of approximately £500,000, assuming an exchange rate of 11.87NOK/GBP.
For further information, please contact:



Intuitive Investments Group plc


www.iigplc.com




David Evans, Executive Chairman
Robert Naylor, CEO


Via Walbrook PR




 


 




Strand Hanson Limited - Nominated Adviser


+44 (0) 20 7409 3494




James Harris / James Dance / James Bellman
 


 
 
























Turner Pope Investments (TPI) Ltd - Broker


+44 (0) 20 3657 0050




Andrew Thacker / Zoe Alexander


 




 


 




Walbrook PR Limited - Media & Investor Relations


+44 (0)20 7933 8780 or intuitive@walbrookpr.com




Sam Allen / Paul McManus


+44 (0)7502 558 258 / +44 (0) 7980 541 893



 
About Intuitive Investments Group plc
The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCBFLFXFXLEBBQ